We are live on
!
Find out more
CC
Commodore Capital Portfolio holdings
AUM
$1.73B
1-Year Est. Return
298.96%
This Fund
S&P 500
This Quarter
Est. Return
+43.14%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.36B
AUM Growth
-$236M
(-15%)
Cap. Flow
-$42.9M
Cap. Flow
% of AUM
-3.14%
Top 10 Holdings %
Top 10 Hldgs %
69.81%
Holding
40
New
4
Increased
10
Reduced
8
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$70M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$63.7M |
| 3 |
Nurix Therapeutics
NRIX
|
+$30.9M |
| 4 |
Scholar Rock
SRRK
|
+$30.9M |
| 5 |
MRUS
Merus
MRUS
|
+$25.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celldex Therapeutics
CLDX
|
+$55M |
| 2 |
Perspective Therapeutics
CATX
|
+$44.7M |
| 3 |
Kura Oncology
KURA
|
+$35.2M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$34.1M |
| 5 |
Arvinas
ARVN
|
+$29.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.44% |
| 2 | Financials | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBOT
26
BridgeBio Oncology
BBOT
$707M
| $5.25M | 0.38% |
500,000
| – | – |
|
27
Celcuity
CELC
$4.03B
| $5.24M | 0.38% |
400,000
-1,122,332
| -74% | -$15.8M |
|
28
VistaGen Therapeutics
VTGN
$9.29M
| $4.65M | 0.34% |
1,575,000
| – | – |
|
29
Avalo Therapeutics
AVTX
$976M
| $3.59M | 0.26% |
483,000
| – | – |
|
|
THRD
30
DELISTED
Third Harmonic Bio
THRD
| $2.45M | 0.18% |
237,704
-1,122,865
| -83% | -$14M |
|
31
Nkarta
NKTX
$162M
| $876K | 0.06% |
351,848
-4,310,225
| -92% | -$13.3M |
|
|
32
Arvinas
ARVN
$518M
| – | – |
-1,200,000
| Closed | -$29.6M |
|
33
Cabaletta Bio
CABA
$439M
| – | – |
-1,100,000
| Closed | -$5.19M |
|
|
34
Perspective Therapeutics
CATX
$332M
| – | – |
-3,350,000
| Closed | -$44.7M |
|
35
C4 Therapeutics
CCCC
$376M
| – | – |
-3,410,384
| Closed | -$19.4M |
|
|
36
Celldex Therapeutics
CLDX
$2.77B
| – | – |
-1,618,937
| Closed | -$55M |
|
|
37
Kura Oncology
KURA
$922M
| – | – |
-1,800,000
| Closed | -$35.2M |
|
|
38
Rhythm Pharmaceuticals
RYTM
$7B
| – | – |
-650,000
| Closed | -$34.1M |
|
39
Syndax Pharmaceuticals
SNDX
$1.84B
| – | – |
-885,000
| Closed | -$17M |
|
40
Instil Bio
TIL
$48.4M
| – | – |
-150,929
| Closed | -$10.2M |
|
Similar funds
RIA
PAIM
MCWS
VCA
ESBC
MSR
WJA
OMC
Commodore Capital's Q4 2024 Portfolio in Review
As of Q4 2024, Commodore Capital held 40 positions worth $1.36B, down 15% from $1.6B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Commodore Capital withdrew a net $42.9M in Q4 2024, closing 9 positions and reducing 8 holdings. Its most notable exit was Celldex Therapeutics, an estimated $55M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Commodore Capital opened a new position in Scholar Rock worth $41.1M.
- Commodore Capital's largest Q4 2024 buy was Scholar Rock: 950,000 shares worth $41.1M.
- Commodore Capital added most to Vaxcyte in Q4 2024, an estimated $70M increase.
- Commodore Capital's biggest Q4 2024 reduction was Definium Therapeutics, cutting an estimated $25.4M.
- Commodore Capital fully exited Celldex Therapeutics in Q4 2024, selling an estimated $55M.
- Commodore Capital's ten largest holdings make up 70% of its $1.36B portfolio in Q4 2024.
- Commodore Capital opened 4 new positions and closed 9 in Q4 2024.
- Commodore Capital's portfolio value fell 15% quarter-over-quarter to $1.36B.
Based on Commodore Capital's 13F filing for Q4 2024, filed 14 Feb 2025.